TKPYY - Takeda Pharmaceutical Company Limited

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Moody's

    Nidda Healthcare Holding GMBH -- Moody's affirms Nidda's B3 CFR following M&A transactions; stable outlook

    Moody's Investors Service ("Moody's") has today affirmed Nidda BondCo GmbH's ("Nidda" or "the group") B3 corporate family rating and B3-PD probability of default rating (PDR). Concurrently, Moody's has affirmed the B2 ratings on the E735 million 1st lien senior secured notes, the existing E406 million and E235 million 1st lien term loan B, the E759 million and GBP 266 million term loan C, and the E400 million revolving credit facility, all issued by Nidda Healthcare Holding GmbH ("Nidda Healthcare"); and assigned a B2 rating to the add-on term loan E and the tap on the existing senior secured notes, which in total will be E760 million.

  • Moody's

    Shire Acq Inv Ireland Designated Activity Co -- Moody's announces completion of a periodic review of ratings of Takeda Pharmaceutical Company Limited

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Takeda Pharmaceutical Company Limited and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Moody's

    Shire Acq Inv Ireland Designated Activity Co -- Moody's announces completion of a periodic review of ratings of Shire Acq Inv Ireland Designated Activity Co

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Shire Acq Inv Ireland Designated Activity Co and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Moody's

    Shire Acq Inv Ireland Designated Activity Co -- Moody's upgrades Shire's debt ratings to Baa2; stable outlook

    Moody's Investors Service ("Moody's") upgraded the senior unsecured debt ratings of Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC") and Baxalta Incorporated ("Baxalta"), subsidiaries of Shire plc (collectively "Shire") to Baa2 from Baa3. At the same time, Moody's withdrew the issuer rating on Shire plc. Please refer to the Moody's Investors Service's Policy for Withdrawal of Credit Ratings, available on its website, www.moodys.com.

  • Reuters

    Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

    A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year. Takeda Pharmaceutical Co Ltd plans to seek approval for the experimental vaccine first in countries where the virus is endemic, rather than starting with the United States or Europe, whose rigorous reviews are often used as a benchmark worldwide, company executives told Reuters. The strategy mirrors one used by Sanofi SA, which licensed the world's first dengue vaccine, Dengvaxia, in endemic markets in 2015 before attempting to get approval from Western regulators, and forecast up to $1 billion in annual sales.

  • Reuters

    Takeda dengue vaccine meets main goal of trial; detailed results to come

    Takeda Pharmaceutical Co said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the Japanese drugmaker's late-stage clinical trial. Takeda did not disclose how the vaccine performed in people who had never been previously exposed to dengue, a group that experienced an increased risk of severe disease with Sanofi's Dengvaxia, the world's first dengue vaccine. Sanofi had not collected blood samples on all subjects prior to beginning its trials.